← back to search

Barry M. Brenner

UCLA Health ·
Area of research
Nephrology · Cardiology and Cardiovascular Medicine
Research interest
Research interests include Chronic Kidney Disease and Diabetes, Blood Pressure and Hypertension Studies, Dialysis and Renal Disease Management, and Renin-Angiotensin System Studies.
h-index
109
citations
60,955
works
379
NIH funding
primary concept
Medicine
email

Recent publications

Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial
American Journal of Kidney Diseases 2023cited by 27position: middledoi
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
New England Journal of Medicine 2019cited by 5,918position: middledoi
Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials
The Lancet Diabetes & Endocrinology 2019cited by 364position: middledoi
Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies
The Lancet Diabetes & Endocrinology 2019cited by 315position: middledoi
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups
Circulation 2019cited by 286position: middledoi
Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis
European Heart Journal 2018cited by 322position: middledoi
The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics
American Journal of Nephrology 2017cited by 238position: middledoi
A developmental approach to the prevention of hypertension and kidney disease: a report from the Low Birth Weight and Nephron Number Working Group
The Lancet 2017cited by 183position: middledoi
Birth weight, malnutrition and kidney-associated outcomes—a global concern
Nature Reviews Nephrology 2015cited by 291position: lastdoi
Effect of fetal and child health on kidney development and long-term risk of hypertension and kidney disease
The Lancet 2013cited by 550position: middledoi
Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes
New England Journal of Medicine 2012cited by 1,313position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Dick de Zeeuw · University Medical Center Groningen4 papers (2012–2019)Tom Greene · University of Utah3 papers (2017–2019)Carol A. Pollock · Macquarie University3 papers (2017–2019)Christopher P. Cannon · Harvard University3 papers (2017–2019)Vlado Perkovic · UNSW Sydney3 papers (2017–2019)Hiddo J.L. Heerspink · Kidney Associates3 papers (2017–2019)Kenneth W. Mahaffey · Stanford University3 papers (2017–2019)Adeera Levin · Providence Health Care3 papers (2017–2019)David C. Wheeler · University College London3 papers (2017–2019)Bruce Neal · ProCure (United States)3 papers (2017–2019)David M. Charytan · NYU Langone Health3 papers (2017–2019) · 3 papers (2017–2019)Bernard Zinman · Lunenfeld-Tanenbaum Research Institute3 papers (2017–2019)Robert Edwards · Lake Erie College of Osteopathic Medicine3 papers (2017–2019)Meg Jardine · Smart Material (Germany)3 papers (2017–2019)George L. Bakris · University of Mississippi3 papers (2017–2019)Séverine Bompoint · The George Institute for Global Health2 papers (2019–2019) · 2 papers (2019–2019)Rajiv Agarwal · Brigham and Women's Hospital2 papers (2017–2019)Valérie A. Luyckx · London School of Hygiene & Tropical Medicine2 papers (2013–2015)